US2012077771A1PendingUtilityA1

Compositions for use in cardioplegia comprising esmolol and adenosine

24
Individually held — no corporate assignee on recordPriority: Feb 26, 2009Filed: Feb 26, 2010Published: Mar 29, 2012
Est. expiryFeb 26, 2029(~2.6 yrs left)· nominal 20-yr term from priority
Inventors:Hazem FallouhJonathan C. KentishDavid J. Chambers
A61P 41/00A61P 9/00A61K 31/7076A61K 31/24A61K 9/08A61K 33/06A61K 31/216
24
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention related to a composition for use in cardioplegia, said composition comprising (i) esmolol; and (ii) adenosine, wherein in use the concentration of said esmolol is in the range 0.3-1.5 mM, and wherein in use the concentration of said adenosine is in the range 0.1-1.5 mM. The invention also relates to methods of making and using such compositions.

Claims

exact text as granted — not AI-modified
1 . A composition for use in cardioplegia, said composition comprising
 (i) esmolol; and   (ii) adenosine,   wherein in use the concentration of said esmolol is in the range 0.3-1.5 mM, and   wherein in use the concentration of said adenosine is in the range 0.1-1.5 mM.   
     
     
         2 . A composition according to  claim 1  wherein the concentrations of esmolol and adenosine correspond to a single point in the enclosed area on the graph of  FIG. 4 . 
     
     
         3 . A composition according to  claim 2  wherein the concentrations of esmolol and adenosine correspond to a single point in the hatched area on the graph of  FIG. 4 . 
     
     
         4 . A composition according to  claim 1 , wherein the product of the concentration of esmolol and of adenosine is at least 0.15. 
     
     
         5 . A composition according to  claim 4  wherein the product of the concentration of esmolol and of adenosine is at least 0.3. 
     
     
         6 . A composition according to  claim 1 , wherein said composition comprises a blood preparation. 
     
     
         7 . A composition according to  claim 1 , wherein said composition comprises a crystalloid preparation. 
     
     
         8 . A composition according to  claim 1  wherein said composition comprises 0.6 mM esmolol and 0.25 mM adenosine. 
     
     
         9 . A composition according to  claim 1 , wherein said esmolol and adenosine are dissolved in a solvent consisting essentially of Ringer solution. 
     
     
         10 . A composition according to  claim 1 , further comprising 10 mM Mg 2+ . 
     
     
         11 . A method of inducing cardioplegia comprising administering to a subject a composition according to  claim 1 . 
     
     
         12 .- 14 . (canceled) 
     
     
         15 . An ampoule comprising
 (i) 25 mM adenosine   (ii) 60 mM esmolol   in aqueous solution.   
     
     
         17 .- 19 . (canceled) 
     
     
         20 . The method according to  claim 11  wherein said composition is administered at 22-24 degrees Celsius. 
     
     
         21 . A composition for use in manufacture of a cardioplegic solution, said composition comprising a stock solution of esmolol and adenosine, wherein upon dilution of said stock solution for use in a subject the stock solution can be diluted to a concentration of said esmolol in the range 0.3-1.5 mM and the concentration of said adenosine in the range 0.1-1.5 mM. 
     
     
         22 . The composition of  claim 21 , wherein said stock solution comprises esmolol in the concentration range 0.6-150 mM and adenosine in the concentration range 0.2-150 mM.

Join the waitlist — get patent alerts

Track US2012077771A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.